What's Happening?
The More Life Company has signed a strategic letter of intent with an established U.S. 503A compounding pharmacy to develop, compound, and commercialize Quicksome-enabled prescription compounded products in the United States. This partnership provides
a commercial channel for More Life's patented Quicksome platform, a desiccated liposomal formulation that dissolves under the tongue in minutes. The U.S. pharmacy partner will handle compounding, formulation, dispensing, national fulfillment, and telemedicine capabilities, while More Life will provide its delivery technology under a proposed licensing model. This agreement follows recent human pharmacokinetic data demonstrating that Quicksome sublingual tablets of testosterone achieved peak serum levels within 10 to 30 minutes. The initial focus for compounded products will be on hormones and peptides, leveraging the 503A compounding channel as a faster route to market compared to traditional drug approval processes.
Why It's Important?
This development is significant for the U.S. pharmaceutical market, particularly in the rapidly growing compounding sector. The partnership allows The More Life Company to access the U.S. market without the extensive capital and time required for full drug approval, utilizing the 503A compounding pathway. This could lead to the introduction of new, differentiated delivery methods for hormones and peptides, potentially offering patients more convenient and effective treatment options, such as needle-free sublingual tablets. The U.S. compounding pharmacy market is projected to reach approximately $12.8 billion by 2035, with 503A pharmacies accounting for a substantial portion. This collaboration positions More Life to capture a share of this market, especially in areas like men's health and women's hormone therapy, which are significant drivers of the telemedicine boom. The licensing model also represents a capital-light strategy for More Life, focusing on intellectual property while leveraging existing infrastructure.
What's Next?
The next steps involve completing due diligence and finalizing definitive documentation for the licensing agreement. Following this, the focus will shift to operational readiness, including installing and validating Quicksome equipment and processes within the partner's U.S. pharmacy. The companies will then select the initial hormone and peptide formulations for prescription compounding. Concurrently, business development efforts will expand to engage other telemedicine platforms, healthcare organizations, and pharmaceutical developers interested in Quicksome-enabled products. Future milestones also include potential FDA action on peptides, which could further clarify the regulatory landscape for compounded products, and the generation of more human data across various molecules. The success of this partnership could pave the way for additional product offerings and broader market penetration for More Life's delivery technology.
Beyond the Headlines
This strategic partnership highlights the evolving landscape of pharmaceutical innovation and market access in the U.S., particularly the role of compounding pharmacies and telemedicine in bringing new formulations to patients. The use of the 503A compounding pathway, while offering speed to market, also underscores the regulatory complexities and distinctions between FDA-approved drugs and compounded medications. The success of a sublingual delivery system for hormones and peptides could disrupt traditional administration methods, potentially improving patient adherence and overall treatment experience. Furthermore, the emphasis on telemedicine relationships within this partnership reflects the increasing integration of virtual care into pharmaceutical distribution. This model could set a precedent for other technology companies seeking to enter the U.S. market with novel drug delivery systems, emphasizing strategic alliances over direct, costly drug development and approval processes.
